CLAIMS

1. A pharmaceutical combination comprising (i) firibastat, (ii) a diuretic and (iii) a blocker of the systemic renin-angiotensin system selected from the group consisting of angiotensin I converting enzyme inhibitors and angiotensin II receptor type 1 antagonists, for use in the treatment of arterial hypertension or indirectly or directly related diseases, especially heart failure.

2. The pharmaceutical combination according to claim 1, wherein the diuretic is selected from the group consisting of chlorothiazide, hydrochlorothiazide, chlorthalidone, indapamide, furosemide, torsemide, amiloride, triamterene, spironolactone and eplerenone, more preferably the diuretic is selected from the group consisting of hydrochlorothiazide, chlorthalidone, indapamide, and amiloride.

3. The pharmaceutical combination according to claim 1 or 2, wherein the diuretic is hydrochorothiazide.

4. The pharmaceutical combination according to any one of the preceding claims, wherein the blocker of the systemic renin-angiotensin system is selected from the group of angiotensin converting enzyme inhibitors consisting of lisinopril, enalapril, quinapril, ramipril, benazepril, captopril, cilazapril, fosinopril, imidapril, moexipril, trandolapril, or perindopril, more preferably the angiotensin converting enzyme inhibitor is seleted from the group consisting of enalapril, perindopril, ramipril, lisinopril and benazepril.

5. The pharmaceutical combination according to any one of the preceding claims, wherein the blocker of the systemic renin-angiotensin system is enalapril.

6. The pharmaceutical combination according to any one of the claims 1 to 3, wherein the blocker of the systemic renin-angiotensin system is selected from the group consisting of angiotensin II receptor type 1 antagonists consisting of losartan, candesartan, irbesartan, telmisartan, valsartan, olmesartan,

eprosartan and azilsartan, more preferably selected from the group consisting of losartan, valsartan, candesartan, irbesartan, and azilsartan.

7. The pharmaceutical combination according to any one of the claims 1 to 3, or Claim 6, wherein the blocker of the systemic renin-angiotensin system is valsartan.

8. The pharmaceutical combination according to claim 1, wherein the diuretic is hydrochlorothiazide and the blocker of the systemic renin-angiotensin system is enalapril.

9. The pharmaceutical combination according to claim 1, wherein the diuretic is hydrochlorothiazide and the blocker of the systemic renin-angiotensin system is valsartan.

10. The pharmaceutical combination according to claim 1, wherein the diuretic is indapamide and the blocker of the systemic renin-angiotensin system is perindopril.

11. The pharmaceutical combination according to claim 1, wherein the diuretic is chlorthalidone and the blocker of the systemic renin-angiotensin system is azilsartan.

12. The pharmaceutical combination according to claim 8, containing firibastat in an amount in the range from 100 to 1500 mg, hydrochlorothiazide in an amount in the range from 5 to 30 mg, and enalapril in an amount in the range from 2.5 to 50 mg.

13. The pharmaceutical combination according to claim 8, containing firibastat in an amount in the range from 300 to 600 mg, hydrochlorothiazide in an amount in the range from 5 to 15 mg, and enalapril in an amount in the range from 2.5 to 15 mg.

14. The pharmaceutical combination according to any one of claims 1-13, wherein the three active ingredients are administered simultaneously or sequentially, preferably simultaneously administered.

15. A kit of parts comprising a pharmaceutical combination containing (i) firibastat, (ii) a diuretic, (iii) a blocker of the systemic renin-angiotensin system selected from the group consisting of angiotensin I converting enzyme inhibitors and angiotensin II receptor type 1 antagonists, in the form of one, two or three separate units of the components (i) to (iii), for a simultaneous or sequential administration, preferably for simultaneous administration.

16. The kit according to claim 15, wherein (ii) the diuretic is selected from the group consisting of hydrochorothiazide, indapamide, amiloride and chlorthalidone, and (iii) the blocker of the systemic renin-angiotensin system is selected from the group consisting of angiotensin I converting enzyme inhibitors consisting of enalapril, perindopril, ramipril and benazepril or from angiotensin II receptor type 1 antagonists the group consisting of losartan, valsartan, candesartan, irbesartan and azilsartan.

17. The kit according to claim 15, wherein (ii) the diuretic is hydrochlorothiazide and (iii) the blocker of the systemic renin-angiotensin system is enalapril.

18. The kit according to claim 15, wherein (ii) the diuretic is hydrochlorothiazide and (iii) the blocker of the systemic renin-angiotensin system is valsartan.

19. The kit according to claim 15, wherein (ii) the diuretic is indapamide and (iii) the blocker of the systemic renin-angiotensin system is perindopril.

20. The kit according to claim 15, wherein (ii) the diuretic is chlorthalidone and (iii) the blocker of the systemic renin-angiotensin system is azilsartan.

21. The kit according to any one of claims 15-20, which is suitable for the treatment of hypertension and related diseases and conditions.

22. The use of (i) firibastat, (ii) a diuretic and (iii) a blocker of the systemic renin-angiotensin system selected from the group consisting of angiotensin I converting enzyme inhibitors and angiotensin II receptor type 1 antagonists for the manufacture of a medicament for the treatment of arterial hypertension or indirectly or directly related diseases, especially heart failure.

23. The use of claim 22 wherein he diuretic is hydrochlorothiazide and the blocker of the systemic renin-angiotensin system is enalapril.